603127 昭衍新药
交易中 07-22 09:44:59
资讯
新帖
简况
昭衍新药（603127）披露完成股份性质变更暨2026年A股限制性股票激励计划实施进展，7月20日股价下跌1.94%
证券之星 · 07-20 22:04
昭衍新药（603127）披露完成股份性质变更暨2026年A股限制性股票激励计划实施进展，7月20日股价下跌1.94%
Barclays PLC增持昭衍新药(06127)约327.98万股 每股作价约24.25港元
智通财经 · 07-20 19:32
Barclays PLC增持昭衍新药(06127)约327.98万股 每股作价约24.25港元
当一家CRO的利润由实验猴重估，账面繁荣为何盖不住主业失血
华夏时报网 · 07-20 15:18
当一家CRO的利润由实验猴重估，账面繁荣为何盖不住主业失血
CRO概念板块短线走低，灵康药业、昭衍新药、美诺华跌停
每日经济新闻 · 07-20 09:39
CRO概念板块短线走低，灵康药业、昭衍新药、美诺华跌停
每周股票复盘：昭衍新药（603127）上半年净利预增884.9%
证券之星 · 07-19
每周股票复盘：昭衍新药（603127）上半年净利预增884.9%
昭衍新药(06127)：李晶莹获委任为联席公司秘书
智通财经 · 07-17
昭衍新药(06127)：李晶莹获委任为联席公司秘书
港股异动 | 昭衍新药(06127)再跌超11% 公司发布风险提示公告 实验猴涨价贡献绝大多数纯利
智通财经 · 07-17
港股异动 | 昭衍新药(06127)再跌超11% 公司发布风险提示公告 实验猴涨价贡献绝大多数纯利
异动快报：昭衍新药（603127）7月17日9点40分触及跌停板
证券之星 · 07-17
异动快报：昭衍新药（603127）7月17日9点40分触及跌停板
“一猴难求”推动市值三天飙涨70亿元，昭衍新药提示风险
长安街知事 · 07-16
“一猴难求”推动市值三天飙涨70亿元，昭衍新药提示风险
昭衍新药股价异动，一机构席位近三个交易日卖出约5.61亿元
北京商报 · 07-16
昭衍新药股价异动，一机构席位近三个交易日卖出约5.61亿元
昭衍新药(06127)A股股票交易异常波动 不存在应披露而未披露的重大信息
智通财经 · 07-16
昭衍新药(06127)A股股票交易异常波动 不存在应披露而未披露的重大信息
昭衍新药：存在市场情绪过热、非理性炒作风险
格隆汇 · 07-16
昭衍新药：存在市场情绪过热、非理性炒作风险
7月16日医疗服务板块持续上行 昭衍新药涨停
央广财经 · 07-16
7月16日医疗服务板块持续上行 昭衍新药涨停
A股开盘速递 | A股集体低开 沪指跌1.09% 存储芯片等板块跌幅居前
智通财经网 · 07-16
A股开盘速递 | A股集体低开 沪指跌1.09% 存储芯片等板块跌幅居前
昭衍新药：公司严格遵循相关信息披露规定
证券之星 · 07-15
昭衍新药：公司严格遵循相关信息披露规定
昭衍新药净利最高增13.8倍：CXO破冰，先从一群实验猴开始
港股研究社 · 07-15
昭衍新药净利最高增13.8倍：CXO破冰，先从一群实验猴开始
靠“猴”不靠“药”，昭衍新药利润大增、股价新高难掩主业低迷困境
蓝鲸财经 · 07-15
靠“猴”不靠“药”，昭衍新药利润大增、股价新高难掩主业低迷困境
CRO板块集体大涨！猴价突破20万大关，A股“猴茅”昭衍新药业绩预增10倍
红星资本局 · 07-15
CRO板块集体大涨！猴价突破20万大关，A股“猴茅”昭衍新药业绩预增10倍
昭衍新药（603127）披露2026年半年度业绩预告，7月14日股价上涨7.0%
证券之星 · 07-14
昭衍新药（603127）披露2026年半年度业绩预告，7月14日股价上涨7.0%
“猴哥”发力，昭衍新药预计上半年扣非净利润增超2334%
财闻 · 07-14
“猴哥”发力，昭衍新药预计上半年扣非净利润增超2334%
加载更多
公司概况
公司名称：
北京昭衍新药研究中心股份有限公司
所属行业：
研究和试验发展
上市日期：
2017-08-25
主营业务：
北京昭衍新药研究中心股份有限公司的主营业务是以药物非临床安全性评价服务为主的药物临床前研究服务和实验动物及附属产品的销售业务。公司的主要产品或服务是药物非临床研究服务、临床服务及其他、实验模型供应。公司同时具备中国NMPA、美国FDA、经合组织OECD、韩国MFDS、日本PMDA等GLP资质；2025年9月公司北京及太仓设施通过了OECD的GLP现场检查及复查。
发行价格：
12.51
{"stockData":{"symbol":"603127","market":"SH","secType":"STK","nameCN":"昭衍新药","latestPrice":50.5,"timestamp":1784684699000,"preClose":49.12,"halted":0,"volume":20151409,"delay":0,"changeRate":0.0281,"floatShares":630000000,"shares":749000000,"eps":0.6607,"marketStatus":"交易中","change":1.38,"latestTime":"07-22 09:44:59","open":48,"high":50.8,"low":47.96,"amount":1001000000,"amplitude":0.0578,"askPrice":50.53,"askSize":8,"bidPrice":50.5,"bidSize":14,"shortable":0,"etf":0,"ttmEps":0.6607,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1784691000000},"marketStatusCode":2,"adr":0,"adjPreClose":49.12,"symbolType":"stock","openAndCloseTimeList":[[1784683800000,1784691000000],[1784696400000,1784703600000]],"highLimit":54.03,"lowLimit":44.21,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":749348220,"isCdr":false,"pbRate":4.3,"roa":"--","peRate":76.434085,"roe":"2.82%","epsLYR":0.4,"committee":0.68,"marketValue":37842000000,"turnoverRate":0.032,"status":0,"hkstockBrief":{"symbol":"06127","market":"HK","secType":"STK","nameCN":"昭衍新药","latestPrice":25.8,"timestamp":1784684699946,"preClose":24.8,"halted":0,"volume":3164600,"delay":0,"premium":"-55.88"},"floatMarketCap":31833000000},"requestUrl":"/m/hq/s/603127","defaultTab":"news","newsList":[{"id":"2652821977","title":"昭衍新药（603127）披露完成股份性质变更暨2026年A股限制性股票激励计划实施进展，7月20日股价下跌1.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2652821977","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652821977?lang=zh_cn&edition=full","pubTime":"2026-07-20 22:04","pubTimestamp":1784556262,"startTime":"0","endTime":"0","summary":"截至2026年7月20日收盘，昭衍新药报收于47.0元，较前一交易日下跌1.94%，最新总市值为352.19亿元。近日，昭衍新药发布《关于完成股份性质变更暨2026年A股限制性股票激励计划实施的进展公告》。公告显示，公司已完成2026年A股限制性股票激励计划授予登记，实际向238名激励对象授予263.6300万股限制性股票，授予价格为19.05元/股，认购款总计50,221,515.00元。股份来源为公司从二级市场回购的A股普通股股票，相关股份已由无限售条件流通股变更为有限售条件流通股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072000039186.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1141","399300","BK1576","159982","BK0216","06127","603127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652890218","title":"Barclays PLC增持昭衍新药(06127)约327.98万股 每股作价约24.25港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2652890218","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652890218?lang=zh_cn&edition=full","pubTime":"2026-07-20 19:32","pubTimestamp":1784547178,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，7月15日，Barclays PLC增持昭衍新药327.982万股，每股作价24.2508港元，总金额约为7953.83万港元。增持后最新持股数目约为728.53万股，最新持股比例为6.12%。补充资料：Notifiable interest first occurred due to increase in Equity shares. BBPLCs interests in 2068664 shares long and short and BCSLs interests in 1295444 shares long and 773220 shares short as disclosed at box 22 pertain to an intragroup hedge between BBPLC and BCSL. Interests arising under the hedge are not double counted at BPLCs level.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469911.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["603127","BK1141","06127","BK0216","EWH","BK1576"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652329383","title":"当一家CRO的利润由实验猴重估，账面繁荣为何盖不住主业失血","url":"https://stock-news.laohu8.com/highlight/detail?id=2652329383","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652329383?lang=zh_cn&edition=full","pubTime":"2026-07-20 15:18","pubTimestamp":1784531905,"startTime":"0","endTime":"0","summary":"2026年7月中旬，国内药物非临床CRO龙头企业昭衍新药（603127.SH/06127.HK）成为资本市场焦点。7月14日晚间，公司发布半年度业绩预告，预计上半年实现归母净利润6亿元至9亿元，同比暴增884.9%至1377.4%，远超市场预期。受此消息刺激，公司股价连续三个交易日涨幅偏离值累计超过20%，触发交易异常波动公告。7月17日，开盘11分钟触及跌停。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607203813239470.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607203813239470.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1576","BK1141","BK0216","603127","06127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652126699","title":"CRO概念板块短线走低，灵康药业、昭衍新药、美诺华跌停","url":"https://stock-news.laohu8.com/highlight/detail?id=2652126699","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652126699?lang=zh_cn&edition=full","pubTime":"2026-07-20 09:39","pubTimestamp":1784511595,"startTime":"0","endTime":"0","summary":"7月20日，CRO概念板块短线走低，灵康药业、昭衍新药、美诺华跌停，万邦医药、百奥赛图、百花医药、峆一药业、双成药业等跟跌。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607203812244470.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607203812244470.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06127","BK0056","BK0216","603669","603538","BK0033","BK1141","BK0239","BK1576","603127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652323753","title":"每周股票复盘：昭衍新药（603127）上半年净利预增884.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2652323753","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652323753?lang=zh_cn&edition=full","pubTime":"2026-07-19 01:10","pubTimestamp":1784394618,"startTime":"0","endTime":"0","summary":"截至2026年7月17日收盘，昭衍新药报收于47.93元，较上周的43.22元上涨10.9%。本周关注点来自交易信息汇总：昭衍新药因股价涨幅偏离值累计超20%及日振幅达15%两度登上龙虎榜。来自业绩披露要点：昭衍新药预计2026年上半年归母净利润同比增长884.9%至1,377.4%。昭衍新药因有价格涨跌幅限制的日价格振幅达到15%的前五只证券，于2026年7月14日首次登上龙虎榜。公司股票于2026年7月14日至7月16日连续三个交易日内收盘价格涨幅偏离值累计超过20%，构成交易异常波动。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071900000095.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06127","603127","BK1141","BK0216","BK1576"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652940101","title":"昭衍新药(06127)：李晶莹获委任为联席公司秘书","url":"https://stock-news.laohu8.com/highlight/detail?id=2652940101","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652940101?lang=zh_cn&edition=full","pubTime":"2026-07-17 17:51","pubTimestamp":1784281886,"startTime":"0","endTime":"0","summary":"智通财经APP讯，昭衍新药(06127)发布公告，由于个人工作安排，张嘉伦女士(张女士)已辞任本公司联席公司秘书一职，并不再担任香港联合交易所有限公司(联交所)证券上市规则(上市规则)第 3.05条项下的本公司授权代表(授权代表)，以及上市规则第19A.13(2)条及公司条例(香港法例第622章)第16部项下所规定代表本公司于香港接收法律程序文件及通知的本公司授权代表(法律程序文件代理人)，自2026年7月17日起生效。继张女士辞任后，董事会宣布，李晶莹女士(李女士)已获委任为本公司的联席公司秘书，自2026年7月17日起生效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469075.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06127","BK1576","603127","BK1141","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652476964","title":"港股异动 | 昭衍新药(06127)再跌超11% 公司发布风险提示公告 实验猴涨价贡献绝大多数纯利","url":"https://stock-news.laohu8.com/highlight/detail?id=2652476964","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652476964?lang=zh_cn&edition=full","pubTime":"2026-07-17 10:01","pubTimestamp":1784253703,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，昭衍新药再跌超11%，截至发稿，跌9.76%，报23.3港元，成交额1.85亿港元。消息面上，昭衍新药公告，公司股票连续三个交易日内收盘价格涨幅偏离值累计超过20%，公司股价短期内涨幅较大，存在市场情绪过热、非理性炒作风险，交易风险极大，随时存在股价下跌的风险。期内生物资产公允价值变动贡献净利润7.03亿元至7.77亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1468806.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1576","BK0216","BK1141","603127","BK4588","06127","KCAI","BK4585","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652476335","title":"异动快报：昭衍新药（603127）7月17日9点40分触及跌停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2652476335","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652476335?lang=zh_cn&edition=full","pubTime":"2026-07-17 09:51","pubTimestamp":1784253061,"startTime":"0","endTime":"0","summary":"证券之星7月17日盘中消息，9点40分昭衍新药（603127）触及跌停板。其所属行业医疗服务目前下跌。领涨股为创新医疗。该股为健康中国，AI医疗，医药概念热股。7月16日的资金流向数据方面，主力资金净流出5.14亿元，占总成交额7.73%，游资资金净流入2.53亿元，占总成交额3.8%，散户资金净流入2.61亿元，占总成交额3.93%。近5日资金流向一览见下表：昭衍新药主要指标及行业内排名如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700010809.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","BK1576","603127","BK1141","06127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651447178","title":"“一猴难求”推动市值三天飙涨70亿元，昭衍新药提示风险","url":"https://stock-news.laohu8.com/highlight/detail?id=2651447178","media":"长安街知事","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651447178?lang=zh_cn&edition=full","pubTime":"2026-07-16 20:53","pubTimestamp":1784206380,"startTime":"0","endTime":"0","summary":"7月16日晚，被市场称为“猴茅”的北京昭衍新药研究中心股份有限公司发布股票交易异常波动公告，向市场提示风险。昭衍新药表示，经公司自查并书面征询公司控股股东及实际控制人，截至本公告披露日，公司及公司控股股东、实际控制人确认不存在应披露而未披露的重大信息。公司市值三天累计大涨约77亿元。近年来，创新药研发用实验猴价格大涨，市场出现“一猴难求”现象，而昭衍新药因拥有大量实验猴资源，凭借猴价上涨驱动业绩猛增。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-07-16/doc-inihzfcu7691053.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1576","BK0216","603127","BK1141","06127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651487044","title":"昭衍新药股价异动，一机构席位近三个交易日卖出约5.61亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2651487044","media":"北京商报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651487044?lang=zh_cn&edition=full","pubTime":"2026-07-16 17:56","pubTimestamp":1784195767,"startTime":"0","endTime":"0","summary":"昭衍新药（603127）因成为非S证券连续三个交易日内收盘价格涨幅偏离值累计达到20%的证券登上当日龙虎榜。龙虎榜显示，近三个交易日，买入金额最大的前5名营业部席位累计买入约6.48亿元；卖出金额最大的前五名营业部席位累计卖出约12.19亿元，其中，一机构席位卖出约5.61亿元，居卖方首位。交易行情显示，7月16日，昭衍新药收于53.25元/股，涨幅为5.2%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607163809156262.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607163809156262.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1141","603127","06127","BK0216","BK1576"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651448190","title":"昭衍新药(06127)A股股票交易异常波动 不存在应披露而未披露的重大信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2651448190","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651448190?lang=zh_cn&edition=full","pubTime":"2026-07-16 17:44","pubTimestamp":1784195056,"startTime":"0","endTime":"0","summary":"经自查，公司目前生产经营活动正常，内、外部经营环境未发生重大变化，不存在影响公司股票交易价格异常波动的应披露而未披露的重大信息。其中：生物资产公允价值变动贡献的净利润约人民币7.03亿元到7.77亿元;实验室服务及其他业务净利润约人民币-1.42亿元到6,497.36万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1468497.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["603127","159982","BK1141","399300","06127","BK0216","BK1576"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651177614","title":"昭衍新药：存在市场情绪过热、非理性炒作风险","url":"https://stock-news.laohu8.com/highlight/detail?id=2651177614","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651177614?lang=zh_cn&edition=full","pubTime":"2026-07-16 16:56","pubTimestamp":1784192172,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1141","BK0216","06127","603127","BK1576"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651188974","title":"7月16日医疗服务板块持续上行 昭衍新药涨停","url":"https://stock-news.laohu8.com/highlight/detail?id=2651188974","media":"央广财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651188974?lang=zh_cn&edition=full","pubTime":"2026-07-16 11:10","pubTimestamp":1784171451,"startTime":"0","endTime":"0","summary":"7月16日，医疗服务板块走势持续向好，昭衍新药（603127.SH）涨停，南华生物此前已完成封板，百奥赛图（688796.SH）、普蕊斯（301257.SZ）、泓博医药（301230.SZ）涨幅均超过10%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607163808791024.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1576","BK1141","BK0216","603127","06127","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651497683","title":"A股开盘速递 | A股集体低开 沪指跌1.09% 存储芯片等板块跌幅居前","url":"https://stock-news.laohu8.com/highlight/detail?id=2651497683","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651497683?lang=zh_cn&edition=full","pubTime":"2026-07-16 09:36","pubTimestamp":1784165771,"startTime":"0","endTime":"0","summary":"7月16日，A股三大股指集体低开，沪指跌1.09%，创业板指跌2.48%。","market":"fut","thumbnail":"https://img.zhitongcaijing.com/image/20260716/20260716093643_95554.png?x-oss-process=image/format,jpg/quality,Q_80&image_source=0","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260716/20260716093643_95554.png?x-oss-process=image/format,jpg/quality,Q_80&image_source=0"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1468251.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0188","BK0278","LU1655091616.SGD","LU1781817850.SGD","BK0187","LU0072913022.USD","BK0183","LU0880133367.SGD","BK0028","IE00B0JY6N72.USD","BK0012","000001","LU0067412154.USD","LU1226287529.USD","BK0201","603127","LU1580142542.USD","06127","BK0216","LU1807302812.USD","LU0501845795.SGD","LU1993786604.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651451543","title":"昭衍新药：公司严格遵循相关信息披露规定","url":"https://stock-news.laohu8.com/highlight/detail?id=2651451543","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651451543?lang=zh_cn&edition=full","pubTime":"2026-07-15 17:54","pubTimestamp":1784109254,"startTime":"0","endTime":"0","summary":"证券之星消息，昭衍新药(603127)07月15日在投资者关系平台上答复投资者关心的问题。投资者提问：你好，管理层对公司的信息披露等规定很严，不知道贵公司是不是吃透相关规定以避免相关风险呢？谢谢昭衍新药回复：您好！公司严格遵循相关信息披露规定，感谢关注！本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071500034692.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1141","BK1576","BK0216","603127","06127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651451783","title":"昭衍新药净利最高增13.8倍：CXO破冰，先从一群实验猴开始","url":"https://stock-news.laohu8.com/highlight/detail?id=2651451783","media":"港股研究社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651451783?lang=zh_cn&edition=full","pubTime":"2026-07-15 17:48","pubTimestamp":1784108880,"startTime":"0","endTime":"0","summary":"7月15日昭衍新药在港股高开超过12%，可见资本市场对CXO盈利修复的敏感度非同一般。2025年年度报告显示，昭衍新药当年实现收入16.58亿元，同比下降17.9%，其中非临床研究服务收入15.77亿元，占总收入95.1%；综合毛利率由25.0%降至20.71%，同比下降7.72个百分点。昭衍新药与常规CXO公司不同，其实验猴价格上涨可以同时影响资产价值、项目报价和实验成本，使利润表带有较强的商品周期特征。昭衍新药已经给出CXO行业离开底部的证据，尚未给出全面上行的终局答案。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-07-15/doc-inihwrra4796564.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["CXO","06127","603127","BK1576","BK0216","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651456592","title":"靠“猴”不靠“药”，昭衍新药利润大增、股价新高难掩主业低迷困境","url":"https://stock-news.laohu8.com/highlight/detail?id=2651456592","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651456592?lang=zh_cn&edition=full","pubTime":"2026-07-15 17:06","pubTimestamp":1784106374,"startTime":"0","endTime":"0","summary":"蓝鲸新闻7月15日讯7月15日，昭衍新药（603127.SH）股价大涨，截至收盘，A股股价涨停报50.62元/股，创近4年来新高，总市值为379.32亿元。港股股价大涨25.5%。股价大涨与其最新发布的业绩预告有关，7月14日晚，昭衍新药发布公告称，预计2026年上半年实现营业收入约人民币6.69亿元到7.39亿元，同比增加约0%到10.5%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607153807513866.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1141","BK0216","BK1576","603127","06127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651435044","title":"CRO板块集体大涨！猴价突破20万大关，A股“猴茅”昭衍新药业绩预增10倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2651435044","media":"红星资本局","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651435044?lang=zh_cn&edition=full","pubTime":"2026-07-15 11:22","pubTimestamp":1784085767,"startTime":"0","endTime":"0","summary":"红星资本局7月15日消息，今日开盘，“猴茅”昭衍新药（603127.SH；6127.HK）股价迅速走高。截至发稿，昭衍新药A股股价涨停，报50.62元/股，最新市值344亿元，H股盘中涨超14%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607153807233852.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159982","BK1576","603127","BK0216","BK1141","06127","399300"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651017871","title":"昭衍新药（603127）披露2026年半年度业绩预告，7月14日股价上涨7.0%","url":"https://stock-news.laohu8.com/highlight/detail?id=2651017871","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651017871?lang=zh_cn&edition=full","pubTime":"2026-07-14 22:04","pubTimestamp":1784037866,"startTime":"0","endTime":"0","summary":"截至2026年7月14日收盘，昭衍新药报收于46.02元，较前一交易日上涨7.0%，最新总市值为344.85亿元。该股当日开盘43.11元，最高46.43元，最低40.01元，成交额达29.98亿元，换手率为10.96%。近日，北京昭衍新药研究中心股份有限公司发布2026年半年度业绩预告。公告指出，主要原因为生物资产公允价值上升及自然生长增值。实验室服务业务利润仍受行业竞争影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071400049097.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1576","BK1141","BK0216","06127","603127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651109782","title":"“猴哥”发力，昭衍新药预计上半年扣非净利润增超2334%","url":"https://stock-news.laohu8.com/highlight/detail?id=2651109782","media":"财闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651109782?lang=zh_cn&edition=full","pubTime":"2026-07-14 21:08","pubTimestamp":1784034480,"startTime":"0","endTime":"0","summary":"7月14日盘后，昭衍新药披露业绩预告，预计2026年1—6月实现营业收入约人民币6.69亿元到7.39亿元，与上年同期的数据相比，同比增加约0%到10.5%。营业收入预计小幅增长的情况下，昭衍新药的净利润却出现显著攀升，公司预计2026年1—6月实现归母净利润约人民币6亿元到9亿元，同比增加约884.9%到1377.4%；预计扣非归母净利润同比增长2334.2%到3551.3%。昭衍新药2025年年报显示，报告期内生物资产公允价值变动带来的净收益为4.76亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-07-14/doc-inihusxw8447567.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06127","603127"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1784684700650,"stockEarnings":[{"period":"1week","weight":0.0674},{"period":"1month","weight":0.3816},{"period":"3month","weight":0.3061},{"period":"6month","weight":0.2385},{"period":"1year","weight":0.8821},{"period":"ytd","weight":0.4072}],"compareEarnings":[{"period":"1week","weight":-0.0259},{"period":"1month","weight":-0.0553},{"period":"3month","weight":-0.0589},{"period":"6month","weight":-0.0626},{"period":"1year","weight":0.0856},{"period":"ytd","weight":-0.0263}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"北京昭衍新药研究中心股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"0人","perCapita":"--","listingDate":"2017-08-25","address":"北京市大兴区北京经济技术开发区荣京东街甲5号","registeredCapital":"74934万元","survey":" 北京昭衍新药研究中心股份有限公司的主营业务是以药物非临床安全性评价服务为主的药物临床前研究服务和实验动物及附属产品的销售业务。公司的主要产品或服务是药物非临床研究服务、临床服务及其他、实验模型供应。公司同时具备中国NMPA、美国FDA、经合组织OECD、韩国MFDS、日本PMDA等GLP资质；2025年9月公司北京及太仓设施通过了OECD的GLP现场检查及复查。","listedPrice":12.51},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"昭衍新药(603127)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供昭衍新药(603127)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"昭衍新药,603127,昭衍新药股票,昭衍新药股票老虎,昭衍新药股票老虎国际,昭衍新药行情,昭衍新药股票行情,昭衍新药股价,昭衍新药股市,昭衍新药股票价格,昭衍新药股票交易,昭衍新药股票购买,昭衍新药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"昭衍新药(603127)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供昭衍新药(603127)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}